52 results about "Peripheral neuropathic pain" patented technology

The present invention relates to the use of tarenflurbil and/or a pharmaceutically tolerable salt or derivative thereof in enantiomerically-pure and/or essentially enantiomerically-pure form or a form that is enriched with respect to flurbiprofen racemate and/or a racemate of said salt or derivative, for the production of a drug for the treatment of pain-associated neuropathy, pain-associated neuropathy that is simultaneously accompanied by states of nociceptive pain, peripheral and/or predominantly peripheral neuropathic pain or central and/or predominantly central neuropathic pain.

The invention provides a pharmaceutical composition of duloxetine or its pharmaceutically equivalent derivatives like salts, isomers, complexes, polymorphs, hydrates or esters thereof and at least one buffering agent. The duloxetine or its pharmaceutically equivalent derivative is present from about 2 mg to approximately 200 mg; and the buffering agent is present in an amount of approximately 0.1 mEq to approximately 2.5 mEq per mg of duloxetine. Also provided is a method for treating of major depressive disorder and or diabetic peripheral neuropathic pain comprising administering to a mammal in need of such treatment a therapeutically effective amount of a composition.

The invention refers to the use of a sigma ligand, particularly a sigma ligand of formulae (I), (II) or (III) to prevent and/or treat acute and chronic pain developed as a consequence of surgery, especially superficial and/or deep pain secondary to surgical tissue injury, and peripheral neuropathic pain, neuralgia, allodynia, causalgia, hyperalgesia, hyperesthesia, hyperpathia, neuritis or neuropathy secondary to surgical procedure.

The invention provides for the first time an oral liquid composition of duloxetine or its pharmaceutically equivalent derivatives like salts, isomers, complexes, polymorphs, hydrates or esters thereof. The duloxetine or its pharmaceutically equivalent derivative is present from about 2 mg to approximately 200 mg; and a buffering agent was used to stabilize the acid sensitive duloxetine. The composition has duloxetine from about 0.1 meq to about 2.5 mEq per mg of duloxetine. The invention further discloses an oral liquid composition of duloxetine or its pharmaceutically equivalent derivative wherein the degradation product 1-Naphthol is less than 0.01%. Also provided is a method for treating of major depressive disorder and or diabetic peripheral neuropathic pain comprising administering to a mammal in need of such treatment a therapeutically effective amount of a composition.

The invention refers to a combination comprising a sigma ligand of formula (I) and an opioid or opiate for use in the prevention and/or treatment of pain developed as a consequence of surgery, especially peripheral neuropathic pain, allodynia, causalgia, hyperalgesia, hyperesthesia, hyperpathia, neuralgia, neuritis or neuropathy. The invention also refers to the sigma ligands of formula (I) for use in potentiating the analgesic effect of an opioid or opiate and/or for decreasing the dependency induced thereby when said opioid or opiate is used in the prevention and/or treatment of pain developed as a consequence of surgery.

The invention belongs to the field of traditional Chinese medicine, and particularly relates to a traditional Chinese medicine composition for treating diabetic peripheral neuropathic pain and a preparation method thereof. The traditional Chinese medicine composition is prepared from Semen Coicis, Astragalus root, radix codonopsitis, resina draconis, radix angelicae pubescentis, hemlock parsley, futokadsura stem and liquorice. The traditional Chinese medicine composition provided by the invention has the advantages of obvious treatment effect on diabetic peripheral neuropathic pain, low recurrence rate and no adverse reaction.

Pain, for example, neuropathic pain such as peripheral neuropathic pain, may be treated or alleviated by administering to a subject an effective amount of one or more caspase inhibitors. Activator and effector caspases, defining components of programmed cell death (PCD, apoptosis) signaling pathways, have been found to also contribute to pain-related behavior in animals with small-fiber peripheral neuropathies. The death receptor ligand, tumor necrosis factor alpha (TNFα) and its downstream second messenger, ceramide, also produce pain-related behavior via this mechanism.

The invention belongs to the field of chemical drugs and in particular relates to a transdermal absorption preparation for treating diabetic peripheral neuropathic pain. The transdermal absorption preparation is prepared from gamma-aminobutyric acid analogue-like analgesic and small-molecule tricarbonyl nitrogen-containing compounds, and pharmaceutical excipients of the preparation include Carbomer 940, glycerin, Tween-80, triethanolamine, laurocapram and distilled water. Due to topical drug delivery, the transdermal absorption preparation has an obvious effect of relieving the diabetic peripheral neuropathic pain. Moreover, the dose of the gamma-aminobutyric acid analogue-like analgesic can be reduced.

The invention discloses a traditional Chinese medicine preparation for treating diabetic peripheral neuropathic pain and belongs to the technical field of traditional Chinese medicine. The preparation is prepared from, by weight, 0.5 part of cassia twigs, 0.2 part of radix angelicae, 0.35 part of Chinese mosla herb, 1.3 parts of fructus xanthii, 1.15 parts of peach twigs, 0.55 part of drynaria total flavonoids, 2 parts of schefflera kwangsiensis, 0.35 part of multiflower knotweed vines, 0.05 part of pearl powder, 0.4 part of semen ziziphi spinosae, 1.2 parts of fructus choerospondiatis, 1.25 parts of semen platycladi, 0.3 part of cinnamon, 0.25 part of clove, 0.015 part of fennel, 0.035 part of illicium verum, 0.5 part of prunus mume, 0.45 part of semen litchi, 0.15 part of tangerine seeds and 3 parts of auxiliary materials. The invention further provides a preparation method of the preparation. The traditional Chinese medicine is stable and controllable, and has a remarkable effect on treatment of peripheral neuropathic pain symptoms of diabetic patients. Clinical application verifies that symptom treatment side effects are few, the preparation is soft, harmless and free of addiction, obvious adverse effects do not occur, and the clinical total effective rate of the Chinese medicine reaches 86.7%.

The present disclosure provides a method for the treatment of a neuropathic pain including a central neuropathic pain or a peripheral neuropathic pain in a subject comprising the administration of antibodies that specifically bind to human FAM19A5 and compositions comprising such antibodies. The present disclosure also provides methods for treating a neuropathic pain including a symptom of neuropathic pain, and/or an underlining cause of a neuropathic pain, by administering an antibody that specifically binds to human FAM19A5. In a specific aspect, the method comprises administering antibodies specifically bind to human FAM19A5, e.g., binds to soluble human FAM19A5 with a KD of 10 nM or less, or binds to membrane bound human FAM19A5 with a K_D of 10 nM or less, or both, as measured by a method known in the art, e.g., ELISA.

The present disclosure relates to pharmaceutical compositions containing phenytoin or phenytoin sodium for use in topical pain relief. Use of the pharmaceutical composition of the disclosure reduces peripheral neuropathic pain. The topical pharmaceutical compositions of the disclosure containing phenytoin or phenytoin sodium, surprisingly reduce peripheral neuropathic pain considerably, especially and preferably in the conditions, characterized by a low to moderate grade of peripheral neurogenic inflammation, such as small fiber neuropathy, diabetic neuropathy, chronic idiopathic axonal polyneuropathy, post-herpetic neuralgia, trigeminus neuralgia, chemotherapy induced polyneuropathy, traumatic neuropathies, compression neuropathies, and infectious neuropathies in remission, according to the disclosure.

The present invention concerns methods and compositions that employ peptides that target dorsal root ganglion (DRG) neurons. In particular, the peptides are used to target therapeutic agents, such as proteins, liposomes, or viral particles comprising therapeutic polynucleotides, to one or more peripheral neuropathies or neuropathic pain, for example. In particular cases, the peripheral neuropathies or neuropathic pain is caused directly or indirectly by DRG neuronopathy.

The invention discloses a tetrodotoxin compound preparation which comprises the following components: tetrodotoxin, lidocaine, puerarin and an excipient. The invention also discloses use of the tetrodotoxin compound preparation in the preparation of a medicament for treating neuropathic pain, wherein the neuropathic pain is diabetic peripheral neuropathic pain or neuropathic injury pain. The novel tetrodotoxin compound preparation provided by the invention is used for treating diabetic peripheral neuropathic pain and neuropathic injury pain, and has advantages of small toxic side effect, good analgesic effect and the like.